On May 3, 2022 Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, reported that Dr. William G. Rice, Chairman, President and CEO of Aptose, will participate in the RBC Capital Markets Global Healthcare Conference (Press release, Aptose Biosciences, MAY 3, 2022, View Source [SID1234613360]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2022 RBC Capital Markets Global Healthcare Conference

The Aptose management team also will be hosting 1×1 meetings during the events.